| Finch Therapeutics Group is a clinical-stage microbiome therapeutics company utilizing its Human-First Discovery platform to develop a class of orally administered biological drugs. Co. is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. Co.'s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Co.'s primary product candidate, CP101, is an orally administered microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection. The FNCH average annual return since 2021 is shown above.
The Average Annual Return on the FNCH average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether FNCH average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FNCH average annual return calculation with any dividends reinvested as applicable (on ex-dates).